Several CXCR7-agonists have also been tested in arterial thrombosis [76]; in cerebral stroke [29,30,32,113,114,115], myocardial infarction/ischemic injury (MI/IR) and heart failure [26,27], diseases that are affected by thrombotic complications (Figure 4); and also in pulmonary [104] and hepatic fibrosis [105]. This evidence concerns the gene ACKR3 and heart failure.